Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes
12.5.2026 09:00:00 EEST | Business Wire | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced it will present 11 scientific abstracts at the International Society of Physical and Rehabilitation Medicine (ISPRM) 2026 World Congress. Taking place from May 17th to May 21st in Vancouver, Canada, the presentations will feature key data on optimal dosing strategies, immunogenicity and the potential for sustained long-term treatment response with XEOMIN® (incobotulinumtoxinA), underscoring the company's commitment to advancing the science behind durable clinical outcomes in neurorehabilitation.
"Our presence at ISPRM underscores our deep commitment to advancing the science behind improved patient care," said Stefan König, CEO, Merz Therapeutics. "We believe that by furthering the understanding of long-term treatment efficacy, we can empower clinicians to better support people affected in achieving their functional goals. Our patient-centric research complements this by ensuring we never lose sight of the outcomes that truly matter to patients."
Spasticity is a chronic condition requiring long-term management, and treatment success can be influenced by factors such as appropriate dose, injection intervals and the potential for a patient to develop an immune response that reduces efficacy.1-3 The data presented provides clinicians with valuable insights into optimizing patient care, supporting the principle of persisting with treatment while also addressing how a low risk of immunogenicity is crucial for maintaining therapeutic response.
"Treating spasticity is a long-term journey we take together with people affected by the condition,” said Dr. Stefan Albrecht, CSO, Merz Therapeutics. "Our aim is to offer a therapy option that meets people’s needs today and remains a reliable choice for years to come. This research delivers robust data on key aspects such as immunogenicity, an important factor in ensuring treatment durability and sustained effectiveness as patients’ needs evolve over time."
ISPRM congress attendees can connect with Merz Therapeutics at booth 306 to learn more about the company's research and commitment to improving outcomes in people with spasticity and other movement disorders.
Merz Therapeutics presentations at ISPRM 2026
Topic | Abstract title | Location and Time |
IncobotulinumtoxinA dose optimization | Goal Attainment and Ambulation With Increasing Doses of IncobotulinumtoxinA: A Post Hoc Analysis of the TOWER Study |
Tuesday, May 19, 2026
|
Immunogenicity and potential for long-term efficacy with IncobotulinumtoxinA | A systematic review and meta-analysis of neutralizing antibodies after treatment with abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA across multiple indications | |
Secondary treatment failure with abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA: a systematic review and meta-analysis | ||
IncobotulinumtoxinA in upper-limb spasticity | Improvement in upper limb spasticity patterns in the elderly following treatment with incobotulinumtoxinA: a pooled analysis |
Tuesday, May 19, 2026
|
Moderate-to-severe upper limb spasticity patterns in the elderly are improved following treatment with incobotulinumtoxinA: a pooled analysis |
Tuesday, May 19, 2026
| |
IncobotulinumtoxinA in lower-limb spasticity | IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy: Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE) | |
Paratonia management | Botulinum neurotoxin type-A in the treatment of patients with paratonia | |
Digital integration | Use of a Smartphone App (iFlexo) to Support Rehabilitation in Post-Stroke Spasticity: A Proof-of-Concept Study | |
Patient and caregiver perspectives in spasticity | Measuring spasticity in clinical trials – which endpoints are most relevant to patients? | |
Barriers and facilitators to clinical trial involvement for patients with spasticity | ||
Peripheral neuropathic pain | Paving the Way for a New Local Peripheral Neuropathic Pain Treatment: Proof-of-concept Clinical Trial with IncobotulinumtoxinA (PaiNT) |
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to delivering better outcomes for more patients. With science as its foundation and the patient experience as its focus, the company relentlessly pursues innovative treatments and partnerships to address unmet needs in movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany, and is active in more than 80 countries. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company with a more than 115-year legacy. With passion and purpose, Merz Therapeutics continues to advance care in specialty neurology in ways that benefit both patients and society.
Please visit www.merztherapeutics.com.
References:
- Shtefan V, Fletcher J, Duclos OA. Causes of Botulinum Toxin Treatment Failure. Clin Cosmet Investig Dermatol. 2022;15:1045-1049. Published 2022 Jun 7. doi:10.2147/CCID.S363321.
- Ketchum N, Carda S, O'Dell M, Säterö P, Jacinto J, Deltombe T, Francisco G. Module 4: Optimizing Outcomes in Spasticity Treatment. The Journal of the International Society of Physical and Rehabilitation Medicine 5(Suppl 1):p S50-S60, June 2022. | DOI: 10.4103/2349-7904.347810.
- U.Walter, P.Albrecht, W.Carr, and H.Hefter, “Systematic Review and Meta-Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications,” European Journal of Neurology 32, no. 8 (2025): e70289, https://doi.org/10.1111/ene.70289.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260511033791/en/
Contacts
Media Contact:
Merz Therapeutics GmbH
Luke Anthony Mircea-Willats
Global Communications & Strategic Affairs
merztherapeutics@merz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 09:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-CM that is designed to deliver rapid knockdown of TTR at the source. The data presented at Heart Failure 2026, the annual congress of the Heart Failure Association of the European Society of Cardiology, show consistent clinical benefit across patient populations commonly encountered in clinical practice, including those with a high disease burden, supporting its use as a first-line treatment option for this rapidly progressive and life-threatening disease. “The analyses presented at Heart Failu
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook12.5.2026 08:30:00 EEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 +3.1% Adjusted EBITDA (4) 404 280 +57.0% 425 +5.0% 1) ‘Reported basis’ with Intelsat fully consolidated from 17 July 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralise currency variations 3) ‘Like-for-like basis’ is as if Intelsat fully consolidated from 1 January 2024 4) Excluding operating expenses/income recognised in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +106.0% yoy(1) supported by growth in Mobility (+207.8% yoy(1); including positive impact from a contract restructuring in Aviation) and Gov
GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI12.5.2026 04:00:00 EEST | Press release
GIGABYTE Technology, a global leader in high-performance computing, is taking its most comprehensive end-to-end portfolio for AI infrastructure to COMPUTEX 2026 under the theme "Future Landing." As AI transitions from training into large-scale inference and real-world operation, GIGABYTE addresses the industry's most pressing challenge: not whether AI can be built, but how quickly and reliably it can be deployed, operated, and sustained at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299592/en/ GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI At COMPUTEX, GIGABYTE organizes its showcase around three states that define the lifecycle of production AI infrastructure. Ready: integrated systems that have been fully built, simulated, validated, and prepared for deployment. Deployable: modular clusters engineered for rapid implementation across diverse environments.
INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering11.5.2026 22:49:00 EEST | Press release
INNIO Group ("INNIO"), a leading global distributed energy solutions provider, today announces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511389675/en/ INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. INNIO has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays and Citigroup are acting as book-running managers for the proposed offering. Baird, BNP Paribas
Only 7% of Companies Achieve Full Compliance as Global Expansion Increases Legal Complexity11.5.2026 16:00:00 EEST | Press release
As businesses accelerate their global expansion in 2026, compliance fails to keep pace. In fact, only 7% of organizations report full compliance across their global entities, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 350 general counsel (GCs) and senior legal professionals across Europe, North America, and Asia Pacific to examine how their teams navigate international expansion, regulatory pressure, and the increasing adoption of artificial intelligence (AI).¹ The findings appear in CSC’s latest report, General Counsel Barometer 2026: From Complexity to Control. Most organizations report partial compliance, with over half (53%) estimating they are 50–75% compliant, and a further 35% placing themselves between 76%–99%. This leaves just 7% of organizations reporting full compliance across all global entities. GCs also report low confidence in addressing ongoing demands amid global expansion. More than tw
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom